This study aimed to assess the effectiveness and safety of second-line or higher osimertinib in a real-world setting in patients with EGFR T790M-positive advanced NSCLC who had received prior EGFR-TKI therapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.